The latest price target for OKYO Pharma (NASDAQ:OKYO) was reported by HC Wainwright & Co. on October 24, 2024. The analyst firm set a price target for $7.00 expecting OKYO to rise to within 12 months (a possible 542.20% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for OKYO Pharma (NASDAQ:OKYO) was provided by HC Wainwright & Co., and OKYO Pharma reiterated their buy rating.

There is no last upgrade for OKYO Pharma

There is no last downgrade for OKYO Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OKYO Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OKYO Pharma was filed on October 24, 2024 so you should expect the next rating to be made available sometime around October 24, 2025.

While ratings are subjective and will change, the latest OKYO Pharma (OKYO) rating was a reiterated with a price target of $7.00 to $7.00. The current price OKYO Pharma (OKYO) is trading at is $1.09, which is out of the analyst’s predicted range.